Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfram Jung

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Hematological Oncology|April 3, 2022
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysisEvgenii Shumilov, Justin Hasenkamp, Markus Maulhardt, et al.
Bone Marrow Transplantation|November 11, 2018
Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced diseaseGerald Wulf, Justin Hasenkamp, Wolfram Jung, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 22, 2006
Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantationBarbara C Gärtner, Wolfram Jung, Christoph Welsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphomaChristina Heemann, Markus Kreuz, Irene Stoller, et al.
Frontiers in Immunology|October 25, 2021
Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA AssociationsRebecca Isabel Wurm-Kuczera, Judith Buentzel, Julia Felicitas Leni Koenig, et al.
The Lancet. Haematology|October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trialsBastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
European Journal of Haematology|July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myelomaChristian Straka, Hans Salwender, Stefan Knop, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Blood|October 27, 2007
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Martin Dreyling, Wolfram Klapper, et al.
European Journal of Haematology|June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trialsChristian Straka, Stefan Knop, Martin Vogel, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Hematological Oncology|April 3, 2022
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysisEvgenii Shumilov, Justin Hasenkamp, Markus Maulhardt, et al.
Bone Marrow Transplantation|November 11, 2018
Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced diseaseGerald Wulf, Justin Hasenkamp, Wolfram Jung, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 22, 2006
Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantationBarbara C Gärtner, Wolfram Jung, Christoph Welsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphomaChristina Heemann, Markus Kreuz, Irene Stoller, et al.
Frontiers in Immunology|October 25, 2021
Sarcoidosis Following Hematopoietic Stem Cell Transplantation: Clinical Characteristics and HLA AssociationsRebecca Isabel Wurm-Kuczera, Judith Buentzel, Julia Felicitas Leni Koenig, et al.
The Lancet. Haematology|October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trialsBastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
European Journal of Haematology|July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myelomaChristian Straka, Hans Salwender, Stefan Knop, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Blood|October 27, 2007
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Martin Dreyling, Wolfram Klapper, et al.
European Journal of Haematology|June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trialsChristian Straka, Stefan Knop, Martin Vogel, et al.
Pageof 3